Found: 28
Select item for more details and to access through your institution.
Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET.
- Published in:
- Brain Communications, 2024, v. 6, n. 4, p. 1, doi. 10.1093/braincomms/fcae162
- By:
- Publication type:
- Article
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00939-9
- By:
- Publication type:
- Article
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00939-9
- By:
- Publication type:
- Article
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
- Published in:
- Brain: A Journal of Neurology, 2023, v. 146, n. 4, p. 1592, doi. 10.1093/brain/awac333
- By:
- Publication type:
- Article
Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019, v. 5, n. 1, p. 871, doi. 10.1016/j.trci.2019.11.002
- By:
- Publication type:
- Article
Plasma p‐tau181/Aβ<sub>1‐42</sub> ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ<sub>1‐42</sub> and future cognitive decline.
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022, v. 14, n. 1, p. 1, doi. 10.1002/dad2.12375
- By:
- Publication type:
- Article
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia.
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022, v. 14, n. 1, p. 1, doi. 10.1002/dad2.12285
- By:
- Publication type:
- Article
O5‐05‐02: CSF BIOMARKERS OF SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON‐DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IMPROVE DIAGNOSTIC CLASSIFICATION OF MCI AND AD AND CORRELATE WITH COGNITION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1626, doi. 10.1016/j.jalz.2019.06.4859
- By:
- Publication type:
- Article
O2‐05‐03: CHARACTERIZATION AND TRANSFER OF A NOVEL PLASMA Aβ1‐42/Aβ1‐40 SIMOA ASSAY FOR INTEGRATION INTO THE CLINIC.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P546, doi. 10.1016/j.jalz.2019.06.4477
- By:
- Publication type:
- Article
O1‐07‐04: CSF BIOMARKERS OF AMYLOID, TAU AND SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON‐DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IN CSF AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P212, doi. 10.1016/j.jalz.2019.06.4556
- By:
- Publication type:
- Article
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.
- Published in:
- Annals of Clinical & Translational Neurology, 2022, v. 9, n. 5, p. 734, doi. 10.1002/acn3.51553
- By:
- Publication type:
- Article
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer's disease.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-89004-x
- By:
- Publication type:
- Article
Combination of plasma amyloid beta<sub>(1-42/1-40)</sub> and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology.
- Published in:
- Alzheimer's Research & Therapy, 2020, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13195-020-00682-7
- By:
- Publication type:
- Article
Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082944
- By:
- Publication type:
- Article
Preliminary performance of the Lumipulse G pTau 217 Plasma prototype assay on plasma samples.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079647
- By:
- Publication type:
- Article
Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079533
- By:
- Publication type:
- Article
Plasma ALZpath p‐tau217 for the identification of amyloid and tau positivity.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079892
- By:
- Publication type:
- Article
Plasma phosphorylated tau 217 levels are highly stable under common pre‐analytical sample handling procedures.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.078393
- By:
- Publication type:
- Article
Cross‐sectional investigation of synaptic markers Neurogranin and BACE1 in CSF from the AIBL study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.078048
- By:
- Publication type:
- Article
Point of care measurement of blood tau in Alzheimer's dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.067530
- By:
- Publication type:
- Article
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 5, p. 1913, doi. 10.1002/alz.12841
- By:
- Publication type:
- Article
A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.065391
- By:
- Publication type:
- Article
CSF‐plasma biomarker profiles from BioFINDER MCI patients using the same technology.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.064456
- By:
- Publication type:
- Article
Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.064341
- By:
- Publication type:
- Article
The effects of age and sex on plasma p‐tau181 concentrations in Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.068159
- By:
- Publication type:
- Article
Plasma p‐tau181 concentration accurately predicts clinically diagnosed Alzheimer's Disease cases.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.068059
- By:
- Publication type:
- Article
Predictive value of a plasma p‐tau181‐specific assay for amyloid accumulation in asymptomatic Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.061421
- By:
- Publication type:
- Article
Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.054911
- By:
- Publication type:
- Article